Food and Drug Administration

Dermatologic and Ophthalmic Drugs Advisory Committee

September 10, 2003



The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

Basal Cell Carcinoma, Dr. Robert Stern, MD, FDA (HTM) (PPT)

Recurrence Rates in Primary Basal Cell Carcinoma According to Treatment Modality, Dr. Robert Stern, MD, FDA (HTM) (PPT)

Photodynamic Therapy for BCC With Methyl Aminolevulinate and CureLight 01, Dr. Vidar Hansson, MD, PhD, PhotoCure ASA (PDF)

Methyl Aminolevulinate Cream (MAL) With Curettage and Photodynamic Therapy (PDT) for Basal Cell Carcinoma (BCC), Dr. Brenda Vaughan, MD, et. al., FDA (HTM) (PPT)